Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study

Published: 6 June 2025| Version 1 | DOI: 10.17632/xsgcc434b7.1
Contributor:
Guo Zhou

Description

This dataset contains seven supplementary tables enabling assessment of the disease-modifying effects of early IL-17A inhibitor intervention on psoriasis in a real-world cohort. Table 1 presents baseline laboratory parameters stratified by disease duration:USDD: Psoriasis duration≤1 year,LDD1:Psoriasis duration>1 year;SDD:Psoriasis duration≤2 year,LDD2:Psoriasis duration>2 year. Tables 2-3 identify predictors of PASI 100 achievement at 4 and 52 weeks via logistic regression, demonstrating that shorter disease duration significantly increases the likelihood of achieving PASI 100 at both timepoints. Table 4 compares baseline characteristics and discontinuation rates by recurrence status, showing significantly longer mean disease duration and higher discontinuation rates in the recurrence group. Table 5 establishes predictors of relapse through logistic regression, revealing that each additional year of disease duration increases relapse risk by 3% (OR=1.03, 95%CI=1.007-1.054, p=0.01). Table 6 examines relapse after IL-17A discontinuation in ultra-short disease duration (USDD: Psoriasis duration≤1 year) versus long duration (LDD1:Psoriasis duration>1 year): After adjusting for baseline PASI, BSA, and other confounders, USDD showed 78.8% lower relapse risk (OR=0.212, 95%CI=0.055-0.826, p=0.025). Table 7 compares short disease duration (SDD:Psoriasis duration≤2 year) versus long duration (LDD2:Psoriasis duration>2 year): SDD was associated with 70.5% reduced relapse risk (OR=0.295, 95%CI=0.099-0.874, p=0.028) after similar adjustments.

Files

Categories

Psoriasis, Early Intervention, IL-17A Signaling Pathway

Licence